Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of
Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of Albunex, the firstultrasound contrast agent approved for marketing in the U.S (SCAN8/31/94).
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.